Docket No. G-067US03REG Serial No. 09/603,665

## In the Claims

Claims 1-78 (Cancelled)

Claim 79 (Currently amended): An isolated and purified polypeptide comprising a contiguous span of at least 610 amino acids shown as positions 1 to 1629 of SEQ ID NO.5.

Claim 80 (Currently amended): An isolated and purified polypeptide comprising:—a contiguous span of at least 6 amino acids of SEQ ID NO:5, wherein said contiguous span comprises an amino-acid selected from the group consisting of:

- a contiguous span of at least 6 amino acids of SEQ ID NO:5, wherein said contiguous span comprises an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5;
- b) a contiguous span of at least 6 amino acids of SEQ ID NO:5, wherein said contiguous span comprises a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5;
- a contiguous span of at least 6 amino acids of SEQ ID NO:5, wherein said contiguous span comprises an asparagine at an amino acid position corresponding to position 1967 of SEQ ID NO:5;
- d) a contiguous span of at least 6 amino acids of SEO ID NO:5, wherein said contiguous span comprises a glutarnic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5; andor
- e) a contiguous span of at least 6 amino acids of SEQ ID NO:5, wherein said contiguous span comprises an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5.

Claim 81 (Previously added): The polypeptide of claim 80, wherein said contiguous span comprises an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5.

J\GEN\067.US03.REG\Amend-Resp\Amend.doc/DNB/ssa

Docket No. G-067US03REG Serial No. 09/603,665

Claim 82 (Previously added): The polypeptide of claim 80, wherein said contiguous span comprises a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5.

Claim 83 (Previously added): The polypeptide of claim 80, wherein said contiguous span comprises an asparagine at an amino acid position corresponding to position 1967 of SEQ ID NO:5.

Claim 84 (Previously added): The polypeptide of claim 80, wherein said contiguous span comprises a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5.

Claim 85 (Currently amended): The polypeptide of claim 80, wherein said contiguous span comprises an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5.

Claim 86 (Previously added): A composition comprising an isolated and purified polypeptide, wherein said polypeptide has an amino acid sequence comprising at least 10 contiguous amino acids of SEQ ID NO:5 spanning position(s) selected from the group consisting of:

- a) 1 to 200;
- b) 201 to 400;
- c) 401 to 600;
- d) 601 to 800;
- e) 801 to 1000;
- f) 1001 to 1200;
- g) 1201 to 1400;
- h) 1401 to 1629:
- i) 1694, wherein the amino acid at position 1694 of SEQ ID NO:5 is an asparagine;
- j) 1854, wherein the amino acid at position 1854 of SEQ ID NO:5 is a valine; InGEN/067.US03 REG/Amend-Resp/Amend doc/DNB/ssa

Docket No. G-067US03REG Serial No. 09/603,665

- k) 1967, wherein the amino acid at position 1967 of SEQ ID NO:5 is an asparagine;
- 2017, wherein the amino acid at position 2017 of SEQ ID NO:5 is a glutamic acid; and
- m) 2050, wherein the amino acid at position 2050 of SEQ ID NO:5 is an alanine.

Claim 87 (Previously added): The composition of claim 86, wherein said position(s) are 1 to 200.

Claim 88 (Previously added): The composition of claim 86, wherein said position(s) are 201 to 400.

Claim 89 (Previously added): The composition of claim 86, wherein said position(s) are 401 to 600.

Claim 90 (Previously added): The composition of claim 86, wherein said position(s) are 601 to 800.

Claim 91 (Previously added): The composition of claim 86, wherein said position(s) are 801 to 1000.

Claim 92 (Previously added): The composition of claim 86, wherein said position(s) are 1001 to 1200.

Claim 93 (Previously added): The composition of claim 86, wherein said position(s) are 1201 to 1400.

Claim 94 (Previously added): The composition of claim 86, wherein said position(s) are 1401 to 1629.

 ${\tt J.'GEN'067.US03.REG'Amend-Resp\Amend.doc/DNB/ssa}$ 

Docket No. G-067US03REG Serial No. 09/603,665

Claim 95 (Previously added): The composition of claim 86, wherein said position(s) is 1694.

Claim 96 (Previously added): The composition of claim 86, wherein said position(s) is 1854.

Claim 97 (Previously added): The composition of claim 86, wherein said position(s) is 1967.

Claim 98 (Previously added): The composition of claim 86, wherein said position(s) is 2017.

Claim 99 (Previously added): The composition of claim 86, wherein said position(s) is 2050.

Claim 100 (Previously added): The composition of claim 86, wherein said polypeptide is at least 20 amino acids in length.

Claim 101 (Previously added): The composition of claim 86, wherein said polypeptide is at least 50 amino acids in length.

Claim 102 (Previously added): The composition of claim 86, wherein said polypeptide is at least 100 amino acids in length.

Claim 103 (Previously added): The polypeptide of claim 79, wherein said polypeptide is recombinant.

Claim 104 (Previously added): The polypeptide of claim 86, wherein said polypeptide is recombinant.

Claim 105 (Previously added): The composition of claim 86, further comprising a physiologically acceptable carrier.

J:\GEN\067.US03 REG\Amend-Resp\Amend.doc/DNB/ssa

Docket No. G-067US03REG Serial No. 09/603,665

Claim 106 (Previously added): A method of making the polypeptide of claim 79 comprising the steps of:

- a) obtaining a cell that expresses said polypeptide;
- b) growing said cell under conditions suitable to produce said polypeptide; and
- c) isolating and purifying said polypeptide produced by said cell.

Claim 107 (Previously added): The method of claim 106, wherein said cell is prokaryotic.

Claim 108 (Previously added): The method of claim 106, wherein said cell is eukaryotic.

Claim 109 (Previously added): A method of making the polypeptide of claim 86 comprising the steps of:

- a) obtaining a cell that expresses said polypeptide;
- growing said cell under conditions suitable to produce said polypeptide; and isolating and purifying said polypeptide produced by said cell.

Claim 110 (Previously added): The method of claim 109, wherein said cell is prokaryotic.

Claim 111 (Previously added): The method of claim 109, wherein said cell is eukaryotic.

Claim 112 (Previously added): An isolated or purified antibody that selectively binds to an epitope-containing fragment of the polypeptide of claim 79, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 1 to 1629 of SEQ ID NO:5.

Claim 113 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 1 to 200 of SEQ ID NO:5.

Docket No. G-067US03REG Serial No. 09/603,665

Claim 114 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 201 to 400 of SEQ ID NO:5.

Claim 115 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 401 to 600 of SEQ ID NO:5.

Claim 116 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 601 to 800 of SEQ ID NO:5.

Claim 117 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 801 to 1000 of SEQ ID NO:5.

Claim 118 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 1001 to 1200 of SEQ ID NO:5.

Claim 119 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 1201 to 1400 of SEQ ID NO:5.

Claim 120 (Previously added): The antibody of claim 112, wherein said epitope comprises at least one amino acid corresponding to an amino acid shown at position 1401 to 1629 of SEQ ID NO:5.

Claim 121 (Previously added): An isolated or purified antibody that selectively binds to an epitope-containing fragment of the polypeptide of claim 80, wherein said epitope comprises an amino acid selected from the group consisting of:

Docket No. G-067US03REG Serial No. 09/603,665

- an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5;
- a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5;
- an asparagine at an amino acid position corresponding to position 1967 of SEQ ID NO:5;
- a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5; and
- e) an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5.

Claim 122 (Previously added): The antibody of claim 121, wherein said epitope comprises an asparagine at an amino acid position corresponding to position 1694 of SEQ ID NO:5.

Claim 123 (Currently amended): The antibody of claim 121, wherein said epitope comprises comprises a valine at an amino acid position corresponding to position 1854 of SEQ ID NO:5.

Claim 124 (Currently amended): The antibody of claim 121, wherein said epitope comprises an aparagine as an amino acid position corresponding to position 1967 of SEQ ID NO:5.

Claim 125 (Previously added): The antibody of claim 121, wherein said epitope comprises a glutamic acid at an amino acid position corresponding to position 2017 of SEQ ID NO:5.

Claim 126 (Currently amended): The antibody of claim 121, wherein said epitope comprises an alanine at an amino acid position corresponding to position 2050 of SEQ ID NO:5.

Claim 127 (New) The isolated and purified polypeptide according to claim 80, wherein said polypeptide comprises a contiguous span of at least 10 amino acids.

J:\GEN:067.US03.REG\Amend-Resp\Amend.doc/DNB/ssa